AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Thomas Rutkoski

Thomas Rutkoski

Johnson & Johnson Co. - New Jersey / United States
Medical and Health Sciences / Biochemistry
AD Scientific Index ID: 4383472
-
person_outline Thomas Rutkoski's MOST POPULAR ARTICLES
1-) Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers Cancer cell 28 (3), 384-398, 2015
2-) Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants Cancer cell 35 (5), 738-751. e9, 2019
3-) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036 Cancer cell 19 (4), 556-568, 2011
4-) Tuning the pKa of Fluorescein to Optimize Binding Assays Analytical chemistry 79 (17), 6775-6782, 2007
5-) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys The Journal of pharmacology and experimental therapeutics 313 (2), 578-585, 2005